Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414397 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TSHRCES1KCNN4PTPN1 | |
| SCHEMBL465653 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TSHRCES1KCNN4PTPN1 | |
| SCHEMBL13785277 | 0.81 | ALDH1A1 (0.38) | ALDH1A1TSHRCES1KCNN4PTPN1 | |
| SCHEMBL13785278 | 0.81 | ALDH1A1 (0.38) | ALDH1A1TSHRCES1KCNN4PTPN1 | |
| SCHEMBL7356506 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TSHRKCNN4PTPN1NR1H2 | |
| SCHEMBL1401085 | 0.79 | ALDH1A1 (0.35) | ALDH1A1TSHRKCNN4PTPN1NR1H2 | |
| SCHEMBL4080546 | 0.76 | KCNN4 (0.44) | ALDH1A1TSHRCES1KCNN4PTPN1 | |
| SCHEMBL17091567 | 0.75 | KCNN4 (0.34) | ALDH1A1TSHRCES1KCNN4PTPN1 | |
| SCHEMBL7873896 | 0.71 | ALDH1A1 (0.46) | ALDH1A1TSHRCES1KCNN4MAPK1 | |
| SCHEMBL1229735 | 0.71 | CES1 (0.42) | ALDH1A1TSHRCES1KCNN4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1023284-B1 | ANTI-VIRAL PHARMACEUTICAL COMPOSITIONS CONTAINING SATURATED 1,2-DITHIAHETEROCYCLIC COMPOUNDS | US GOV HEALTH & HUMAN SERV (US) | 2005-11-23 | — | — | EP | claimed |
| EP-0469887-B1 | Acetamide derivatives | ZENECA LTD (GB) | 1994-12-14 | — | — | EP | claimed |
| US-12031173-B2 | Methods of producing polyol lipids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220325305-A1 | METHODS OF PRODUCING POLYOL LIPIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3426638-B1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) | 2020-05-06 | — | — | EP | disclosed |
| US-20190119707-A1 | METHODS OF PRODUCING POLYOL LIPIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-25 | — | — | US | disclosed |
| WO-2017184884-A1 | METHODS OF PRODUCING POLYOL LIPIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-26 | — | — | WO | disclosed |
| EP-1233013-B1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO KK (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-7160874-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-20050070485-A1 | Antagonistic activity to alpha 4 integrin; treating asthma, rheumatoid arthritis; N-[1-N,N-dimethylaminocarbonylcyclopropane-1-ylcarbonyl]-4-({[5-chloro-2-(methylthio)pyrimidine-4-yl]carbonyl}-amino)-L-phenylalanine | AJINOMOTO CO., INC. (JP) | 2005-03-31 | — | — | US | disclosed |
| US-6855706-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2005-02-15 | — | — | US | disclosed |
| EP-0752992-B1 | IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AVENTIS PHARMA SA (FR) | 2001-05-30 | — | — | EP | disclosed |
| US-6033882-A | DERIVED FROM LACTOBACILLUS DELBRUECKII SSP. BULGARICUS. | GENZYME CORPORATION (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0767832-A1 | CHIRAL SYNTHESIS OF 2-HYDROXY CARBOXYLIC ACIDS WITH A DEHYDROGENASE | Genzyme Limited (GB) | 1997-04-16 | — | — | EP | disclosed |
| EP-0752992-A1 | IMIDAZO(1,2-A)INDENO(1,2-E)PYRAZINE-4-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1997-01-15 | — | — | EP | disclosed |
| WO-1996001892-A1 | CHIRAL SYNTHESIS OF 2-HYDROXY CARBOXYLIC ACIDS WITH A DEHYDROGENASE | GENZYME LIMITED (GB) | 1996-01-25 | — | — | WO | disclosed |
| WO-1995026350-A1 | IMIDAZO(1,2-A)INDENO(1,2-E)PYRAZINE-4-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1995-10-05 | — | — | WO | disclosed |
| US-5430060-A | Aldose reductase inhibitor | ZENECA LIMITED (GB) | 1995-07-04 | — | — | US | disclosed |
| US-5270342-A | Acetamide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070485-A1 | Antagonistic activity to alpha 4 integrin; treating asthma, rheumatoid arthritis; N-[1-N,N-dimethylaminocarbonylcyclopropane-1-ylcarbonyl]-4-({[5-chloro-2-(methylthio)pyrimidine-4-yl]carbonyl}-amino)-L-phenylalanine | ITGB4, ITGA4, ITGAL | ALDH1A1 912/4885TSHR 1456/4885CES1 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.